Medicare Loophole Leads to Drug Gouging
Regulations passed in 2006 requiring Medicare to cover the cost of certain drugs combined with a 2003 act preventing price negotiations is allowing pharmaceutical companies to charge whatever they want for their medication. The most recent example is with the company Turing Pharmaceuticals and their toxoplasmosis drug, Daraprim. After acquiring the drug in August, CEO Martin Skreli raised the price 5,000 percent, from $13.50 per tablet to $750. More can be read at The Atlantic with Julie Beck.
This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.